SCHEMBL696010

SCHEMBL696010

N#CC1(N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1201605 0.96 ALDH1A1 (0.30)
Hydrochloric Acid SCHEMBL345144 0.96
Hydrochloric Acid SCHEMBL1273427 0.93
Hypochlorous Acid SCHEMBL2378452 0.90
SCHEMBL1139426 0.86
SCHEMBL75984 0.86
SCHEMBL18614452 0.85
SCHEMBL23311387 0.83 ALDH1A1 (0.46)
SCHEMBL4355800 0.83 ALDH1A1 (0.46)
SCHEMBL20987611 0.83 ALDH1A1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3852880-B1 USE OF A CATHEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIES HOFFMANN LA ROCHE (CH) 2024-08-07 EP claimed
CN-108699044-B Novel pyrrolidine derivatives 豪夫迈·罗氏有限公司 2022-03-04 CN claimed
US-20210315863-A1 USE OF A CATHEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIES HOFFMANN-LA ROCHE INC. (US) 2021-10-14 US claimed
EP-3852880-A1 USE OF A CATHEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIES F. Hoffmann-La Roche AG (CH) 2021-07-28 EP claimed
CN-112839716-A Use of cathepsin S inhibitors to combat formation of anti-drug antibodies 豪夫迈·罗氏有限公司 2021-05-25 CN claimed
US-10689339-B2 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2020-06-23 US claimed
WO-2020058297-A1 USE OF A CATHEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIES F. HOFFMANN-LA ROCHE AG (CH) 2020-03-26 WO claimed
EP-3419970-A1 NOVEL PYRROLIDINE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2019-01-02 EP claimed
US-20180362461-A1 NOVEL PYRROLIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-12-20 US claimed
CN-108699044-A New pyrrolidin derivatives 豪夫迈·罗氏有限公司 2018-10-23 CN claimed
US-20030232863-A1 Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders BAYLY CHRISTOPHER I (CA) 2003-12-18 US claimed
WO-2003041649-A2 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-05-22 WO claimed
WO-2003029200-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-04-10 WO claimed
US-6525036-B2 Treating post-menopausal osteoporosis. MERCK & CO., INC. 2003-02-25 US claimed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO claimed
EP-1248612-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2002-10-16 EP claimed
US-6395897-B1 DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-05-28 US claimed
US-20020052378-A1 Novel compounds and compositions as protease inhibitors Celera Corporation 2002-05-02 US claimed
WO-2001049288-A9 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2001-10-25 WO claimed
WO-2001049288-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-07-12 WO claimed